IL125494A0 - Methods for retreatment of patients afflicted with hepatitis c using consensus interferon - Google Patents

Methods for retreatment of patients afflicted with hepatitis c using consensus interferon

Info

Publication number
IL125494A0
IL125494A0 IL12549497A IL12549497A IL125494A0 IL 125494 A0 IL125494 A0 IL 125494A0 IL 12549497 A IL12549497 A IL 12549497A IL 12549497 A IL12549497 A IL 12549497A IL 125494 A0 IL125494 A0 IL 125494A0
Authority
IL
Israel
Prior art keywords
retreatment
hepatitis
methods
consensus interferon
patients afflicted
Prior art date
Application number
IL12549497A
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL125494A0 publication Critical patent/IL125494A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12549497A 1996-02-05 1997-01-13 Methods for retreatment of patients afflicted with hepatitis c using consensus interferon IL125494A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/595,440 US5980884A (en) 1996-02-05 1996-02-05 Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
PCT/US1997/000340 WO1997027866A1 (en) 1996-02-05 1997-01-13 Methods for retreatment of patients afflicted with hepatitis c using consensus interferon

Publications (1)

Publication Number Publication Date
IL125494A0 true IL125494A0 (en) 1999-03-12

Family

ID=24383236

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12549497A IL125494A0 (en) 1996-02-05 1997-01-13 Methods for retreatment of patients afflicted with hepatitis c using consensus interferon

Country Status (15)

Country Link
US (1) US5980884A (cs)
EP (1) EP0879059A1 (cs)
JP (1) JP2000504010A (cs)
KR (1) KR19990082084A (cs)
CN (1) CN1217660A (cs)
AU (1) AU1531897A (cs)
BR (1) BR9700829A (cs)
CZ (1) CZ231998A3 (cs)
EA (1) EA199800674A1 (cs)
HU (1) HUP9900929A3 (cs)
IL (1) IL125494A0 (cs)
NO (1) NO983410L (cs)
SK (1) SK101798A3 (cs)
WO (1) WO1997027866A1 (cs)
ZA (1) ZA97721B (cs)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE205397T1 (de) * 1996-02-28 2001-09-15 Unihart Corp Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (ru) * 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
CN1245215C (zh) * 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US20050079579A1 (en) * 2001-02-28 2005-04-14 Guangwen Wei Uses of spatial configuration to modulate protein function
US8551469B2 (en) * 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
KR20040037191A (ko) * 2001-09-28 2004-05-04 인터뮨, 인크. 치료 실패 환자에서 ｃ형 간염 바이러스 감염의 치료 방법
PL369129A1 (en) * 2001-09-28 2005-04-18 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
WO2003026589A2 (en) * 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
JP2005508943A (ja) * 2001-10-05 2005-04-07 インターミューン インコーポレイテッド 多相インターフェロン送達プロフィールによる肝炎ウイルス感染症の治療法
JP2005508935A (ja) * 2001-10-05 2005-04-07 インターミューン インコーポレイテッド 肝線維症およびｃ型肝炎ウイルス感染症を治療する方法
EP1461067A1 (en) * 2001-12-07 2004-09-29 Intermune, Inc. Compositions and method for treating hepatitis virus infection
KR20040094692A (ko) * 2002-02-14 2004-11-10 파마셋, 리미티드 변형된 불소화 뉴클레오사이드 유사체
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
TW200500374A (en) 2002-06-28 2005-01-01 Idenlx Cayman Ltd 2' and 3' -nucleoside produrgs for treating flavivridae infections
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
MXPA04012802A (es) 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
SI1576138T1 (sl) 2002-11-15 2017-07-31 Idenix Pharmaceuticals Llc 2'-metil nukleozidi v kombinaciji z interferon in flaviviridae mutacijo
KR20050109918A (ko) 2002-12-12 2005-11-22 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드의 제조 방법
WO2004078127A2 (en) * 2003-02-28 2004-09-16 Intermune, Inc. Continuous delivery methods for treating hepatitis virus infection
AU2003225670A1 (en) * 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
PT2604620T (pt) 2003-05-30 2016-08-18 Gilead Pharmasset Llc Analogos de nucleósido fluorados modificados
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
US20050208019A1 (en) * 2003-08-28 2005-09-22 Guangwen Wei Uses of interferons with altered spatial structure
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
GB2426762A (en) 2004-02-02 2006-12-06 Ambrx Inc Modified human growth hormone polypeptides and their uses
CN1980657A (zh) 2004-05-05 2007-06-13 耶鲁大学 新颖的抗病毒赛菊宁黄质类似物
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
SG158136A1 (en) 2004-09-14 2010-01-29 Pharmasset Inc Preparation of 2`-fluoro-2`- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
CN101137391B (zh) * 2005-03-09 2012-07-18 魏光文 重组高效复合干扰素的用途
EP2305695A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
MX2008004754A (es) 2005-10-11 2009-03-02 Intermune Inc Compuestos y metodos para inhibir la replicacion viral de hepatitis c.
WO2007075876A2 (en) 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
JP5713919B2 (ja) 2008-12-23 2015-05-07 ギリアド ファーマセット エルエルシー ヌクレオシドホスホラミデート
KR20110104074A (ko) 2008-12-23 2011-09-21 파마셋 인코포레이티드 퓨린 뉴클레오시드의 합성
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
CA2764759A1 (en) * 2009-06-09 2010-12-16 Defyrus, Inc. Administration of interferon for prophylaxis against or treatment of pathogenic infection
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
WO2011159930A2 (en) 2010-06-16 2011-12-22 Medtronic, Inc. Damping systems for stabilizing medications in drug delivery devices
AR084044A1 (es) 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
JP5677646B2 (ja) 2011-10-21 2015-02-25 アッヴィ・インコーポレイテッド Ｈｃｖの治療に使用するためのｄａａの（例えばａｂｔ−０７２もしくはａｂｔ−３３３との）併用治療
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
TWI726291B (zh) 2013-01-07 2021-05-01 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
AU2014311827B2 (en) 2013-08-27 2017-09-14 Gilead Sciences, Inc. Combination formulation of two antiviral compounds
CA3022119A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect

Also Published As

Publication number Publication date
EP0879059A1 (en) 1998-11-25
EA199800674A1 (ru) 1999-02-25
BR9700829A (pt) 1998-07-07
WO1997027866A1 (en) 1997-08-07
KR19990082084A (ko) 1999-11-15
AU1531897A (en) 1997-08-22
US5980884A (en) 1999-11-09
NO983410D0 (no) 1998-07-23
HUP9900929A3 (en) 1999-11-29
JP2000504010A (ja) 2000-04-04
SK101798A3 (en) 2000-03-13
HUP9900929A2 (hu) 1999-07-28
CZ231998A3 (cs) 1999-03-17
NO983410L (no) 1998-10-05
ZA97721B (en) 1997-08-01
CN1217660A (zh) 1999-05-26

Similar Documents

Publication Publication Date Title
HUP9900929A3 (en) Methods for retreatment of patients afflicted with hepatitis c using consensus interferon
HUP0002755A3 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
HUP9802324A3 (en) Use of ribavirin and interferon alpha for the treatment of hepatitis c
PL324906A1 (en) Vaccines against viral hepatitis of c type
GB9609932D0 (en) Use of IL-12 and IFN alpha for the treatment of infectious diseases
ZA896864B (en) Method and composition for the treatment and prevention of viral infections
IL129352A0 (en) Benzimidazole-2- carbamates for the treatment of viral infections and cancer
HUP0102033A3 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
EP0717592A4 (en) METHOD AND COMPOSITION FOR TREATING THE APATHIE DEMOTIVATION SYNDROME
ZA944488B (en) System for viral inactivation of blood
AU6588598A (en) Treatment of hepatitis b infection with thymosin alpha 1 and famciclovir
EP0973510A4 (en) USE OF AMANTADINE FOR TREATING HEPATITIS C
EP0446578A3 (en) Methods for the preparation of silanes and polysilanes
ZA948252B (en) Method and composition for treatment of autoimmune hepatitis
EP0472595A4 (en) Method of treatment of hepatitis
HK1016903A (en) Methods for retreatment of patients afflicted with hepatitis c using consensus interferon
FI954127L (fi) Menetelmä C-hepatiitin hoitamiseksi interferonihoitoon reagoimattomissa potilaissa
ZA964094B (en) Compositions and methods for the diagnosis of and vaccination against hepatitis c virus (hcv)
EP1007145A4 (en) BLOOD COLLECTION SYSTEM AND METHOD OF USING SAME
EP0472663A4 (en) Method of treatment of hepatitis
GB9425604D0 (en) Peptides effective for diagnsis of hepatitis C infection
GB9412983D0 (en) Novel types of medical use for amphotericin b
ZA988519B (en) Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C
ZA932603B (en) Treatment of hepatitis with GM-CSF
HK1028207A (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon